Related Experiment Videos
[Plasma donor screening and product safety]
Beitrage Zur Infusionstherapie Und Transfusionsmedizin = Contributions to Infusion Therapy and Transfusion Medicine
|January 1, 1997
Summary
Thorough donor screening and plasma pool testing significantly enhance the safety of plasma-derived products. These measures, including viral marker testing and PCR, effectively minimize viral transmission risks in therapeutics.
Area of Science:
- Virology
- Immunology
- Biotechnology
Context:
- Plasma-derived medicinal products require stringent safety measures beyond manufacturing viral inactivation.
- Source material selection, donor screening, inventory hold, and plasma pool testing are critical for product safety.
- This study evaluates viral safety in plasma donations collected between 1994 and 1996.
Purpose:
- To assess the incidence of viral markers in plasma donations.
- To evaluate the effectiveness of donor screening and plasma pool testing in ensuring product safety.
- To confirm the absence of viral transmission from plasma-derived products following implemented safety protocols.
Summary:
- Viral marker incidence rates (HIV, HCV, HBsAg) were determined per 10^5 donations.
- Elevated ALT levels in donors correlated with HCV genome detection, highlighting its importance as a surrogate marker.
- PCR testing of pilot pools detected HCV and HBV genomes, but not HIV, reinforcing safety measures.
Impact:
- The implemented safety measures, including rigorous screening and viral inactivation, have successfully prevented the transmission of hepatitis and AIDS viruses.
- This study validates the comprehensive safety strategy for plasma-derived products, ensuring patient safety.
- The findings underscore the importance of multi-faceted safety approaches in biopharmaceutical manufacturing.